Drug intelligence / Profile preview

Novo-Helisen Depot (Allergopharma)

Development stage
Unknown
Lead developer
Allergopharma
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

Novo-Helisen Depot (NHD) is a standardized allergen extract preparation used for subcutaneous immunotherapy (SCIT) in patients with house dust mite-induced allergic diseases. It consists of a 50/50 mixture of extracts from *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, which are adsorbed onto aluminum hydroxide to create a depot formulation. This formulation allows for the slow release of allergens, facilitating the induction of peripheral T-cell tolerance and a shift from a Th2-mediated allergic response to a Th1/Treg-mediated immune profile. NHD is indicated for the treatment of moderate-to-severe allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma in both children and adults. The preparation is typically administered in a dose-escalation phase followed by a maintenance phase, although accelerated regimens (such as single-concentration accelerated SCIT) are also utilized to reach maintenance doses more rapidly.

Brand names
Novo-Helisen Depot
Other names
NHD double-mite allergen preparationhouse dust mite allergen extractDermatophagoides pteronyssinus and Dermatophagoides farinae allergen extractNovo-Helisen Depot mite preparation
02

Targets

Der f (Dermatophagoides farinae allergens)House dust mite allergen proteins (Dermatophagoides pteronyssinus)HDM-specific IgE (House dust mite-specific immunoglobulin E)

Beyond the preview

Go deeper on Novo-Helisen Depot (Allergopharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novo-Helisen Depot (Allergopharma).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call